Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas
Authors:
- 12 June 2026
- journal article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (9) , 1029-1045
Abstract
Mismatch repair-deficient (dMMR) sarcomas are rare and incompletely characterized. Here, we studied 39 sarcomas with high microsatellite instability (MSI-H) and/or biallelic MMR gene inactivation (21 MSH2 , 9 MLH1 , 4 PMS2 , 4 MSH6 , 1 EPCAM ). All tumors evaluated with immunohistochemistry (IHC; n = 36) showed loss of MMR protein expression. Eight sarcomas were index neoplasms among the 15 patients with documented Lynch syndrome. Eighteen of 1531 sarcomas (1.2%) in our sequencing database were dMMR, with enrichment in pleomorphic rhabdomyosarcoma (PRMS; 1/5), uterine leiomyosarcoma (LMS; 7/124; 5.6%), and unclassified/undifferentiated pleomorphic sarcoma (UPS; 6/259; 2.3%). MMR IHC screening of independent cases confirmed MMR deficiency in PRMS (2/20), uterine LMS (2/20), and unclassified/UPS (1/20). Two histologic patterns were identified among unclassified/UPS. Ten tumors, designated “distinctive lobulated inflammatory sarcoma” (DLIS), showed lobular architecture, florid inflammation, and histiocytoid, variably pleomorphic neoplastic cells. All 6 patients with DLIS and follow-up (median: 6.0 y; range: 3 mo to 8.6 y) were alive with no evidence of disease (ANED), and 2 DLIS responded completely to immune checkpoint inhibition. A morphologically different group of 6 unclassified high-grade sarcomas showed sheets of epithelioid-to-rhabdoid cells with eosinophilic cytoplasm; among 5 patients with follow-up (median: 1.1 y; range: 4 mo to 6.9 y), only 1 was ANED. Surprisingly, all 3 PRMS patients with follow-up (median: 5.7 y; range: 4.2 to 8.3 y) were ANED, including 2 with complete responses of metastases to systemic therapy. We conclude that PRMS, uterine LMS, and unclassified/UPS showed sufficiently prevalent MMR deficiency to justify prospective MMR IHC screening for Lynch syndrome and to identify patients who might benefit from immune checkpoint inhibition. Histologic subtyping of unclassified sarcomas predicted prognosis and therapeutic response. We propose universal MMR IHC screening of (1) PRMS, (2) uterine LMS, (3) unclassified/UPS, and (4) any sarcoma in a patient with a personal or family history of Lynch syndrome.Keywords
This publication has 40 references indexed in Scilit:
- Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapyEuropean Journal of Cancer, 2024
- DNA mismatch repair deficiency as a biomarker in sarcomaSurgical Oncology Insight, 2024
- Sarcoma in patients with Lynch syndrome and response to immunotherapyJournal of Surgical Oncology, 2023
- Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsJAMA Network Open, 2023
- Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndromeHuman Pathology, 2020
- Targeted next-generation sequencing in the detection of mismatch repair deficiency in endometrial cancersLaboratory Investigation, 2019
- Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinomaLaboratory Investigation, 2018
- Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1Nature Genetics, 2008
- Multiple Leiomyomas of the Esophagus, Lung, and Uterus in Multiple Endocrine Neoplasia Type 1The American Journal of Pathology, 2001
- Hibernomas are Characterized by Homozygous Deletions in the Multiple Endocrine Neoplasia Type I RegionThe American Journal of Pathology, 1999